Open AccessPharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2–12 years on rifampicin for tuberculosis
Author(s) -
Tammy Meyers,
Pearl Samson,
Edward P. Acosta,
Jack Moye,
Ellen Townley,
Sarah Bradford,
Linda Marillo,
Kayla Denson,
Laura Hovind,
Thucuma Sise,
Hedy Teppler,
Sisinyana Ruth Mathiba,
Masebole Masenya,
Anneke C. Hesseling,
Mark F. Cotton,
Paul Krogstad
Publication year - 2019
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002369
Subject(s) - raltegravir , medicine , cohort , regimen , pharmacokinetics , tuberculosis , rifampicin , viral load , cohort study , pharmacology , human immunodeficiency virus (hiv) , pediatrics , gastroenterology , virology , antiretroviral therapy , pathology
Drug-drug interactions limit current antiretroviral treatment options for HIV-infected children with tuberculosis (TB). Rifampicin (RIF) induces UDP-glucuronosyltransferase activity, accelerating the clearance of raltegravir (RAL). We sought to establish an optimal and well tolerated dose of RAL when administered with RIF to HIV and TB co-infected children.